An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors

[1]  H. Tseng,et al.  Microfluidic-Based 18F-Labeling of Biomolecules for Immuno–Positron Emission Tomography , 2011, Molecular imaging.

[2]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[3]  G. Mælandsmo,et al.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth , 2010, Cancer Immunology, Immunotherapy.

[4]  A. Scott,et al.  Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer. , 2010, Cancer biotherapy & radiopharmaceuticals.

[5]  V. Rybin,et al.  68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[7]  Carolyn J Anderson,et al.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. , 2009, Cancer biotherapy & radiopharmaceuticals.

[8]  C. Anderson,et al.  Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). , 2009, Accounts of chemical research.

[9]  Sven H. Hausner,et al.  Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. , 2009, Cancer research.

[10]  M. Koch,et al.  Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse , 2009, British Journal of Cancer.

[11]  E. Diamandis,et al.  Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer , 2009, International journal of cancer.

[12]  N. van Bruggen,et al.  Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma , 2009, The Journal of pathology.

[13]  Joachim Feldwisch,et al.  Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine , 2009, Journal of Nuclear Medicine.

[14]  R. Ralhan,et al.  Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients , 2009, International journal of cancer.

[15]  Tara Heitner,et al.  In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice , 2009, Journal of Nuclear Medicine.

[16]  Anna M. Wu,et al.  Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.

[17]  A. Wu,et al.  Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. , 2008, Bioconjugate chemistry.

[18]  A. Wu,et al.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.

[19]  J. Schalkwijk,et al.  Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. , 2008, Cancer research.

[20]  Anna M Wu,et al.  Antibodies for Molecular Imaging of Cancer , 2008, Cancer journal.

[21]  Mattia Barbareschi,et al.  Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients , 2008, Clinical Cancer Research.

[22]  Sanjiv S. Gambhir,et al.  Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.

[23]  C. Benz,et al.  Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells , 2007, Molecular Cancer Therapeutics.

[24]  J. Marks,et al.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer , 2007, Journal of Molecular Medicine.

[25]  S. Morrison,et al.  Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.

[26]  Martin G Pomper,et al.  Radiolabeled Anti-Claudin 4 and Anti-Prostate Stem Cell Antigen: Initial Imaging in Experimental Models of Pancreatic Cancer , 2007, Molecular imaging.

[27]  S. Gambhir,et al.  PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  W. Weichert,et al.  Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer , 2006, Journal of Clinical Pathology.

[29]  Ruedi Aebersold,et al.  Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. , 2005, Gastroenterology.

[30]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[31]  S. Gambhir,et al.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.

[32]  Andrea Bolognesi,et al.  Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody , 2005, Journal of Cell Science.

[33]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[34]  M Dietel,et al.  ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival , 2004, Journal of Clinical Pathology.

[35]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .

[36]  M. Herlyn,et al.  Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. , 2004, The Journal of investigative dermatology.

[37]  Matthew R Cooperberg,et al.  Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells , 2004, Cancer Research.

[38]  Sanjiv Sam Gambhir,et al.  AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.

[39]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[40]  Y. Arano.  Strategies to reduce renal radioactivity levels of antibody fragments. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[41]  U. Boggi,et al.  Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. , 1995, Cancer research.

[42]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[43]  B. Haynes,et al.  Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells , 1995, The Journal of experimental medicine.

[44]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[45]  H. Tseng,et al.  Microfluidic-Based 18 F-Labeling of Biomolecules for Immuno – Positron Emission Tomography , 2011 .

[46]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.

[47]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[48]  C. Milstein,et al.  Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.

[49]  C. Milstein,et al.  [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .